Adrenal cortex cancer
Drug research and approvals for adrenal cortex cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 37 studies of adrenal cortex cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 37
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 37 recruiting on ClinicalTrials.gov ↗
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.NCT07901582 · Not applicable · National and Kapodistrian University of Athens · starts Nov 22, 2025
- Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and HypertensionNCT07470580 · Not applicable · University Hospital, Toulouse · starts Jun 5, 2026
- Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic HepatitisNCT07378761 · Phase 2 · University Hospital, Montpellier · starts Jun 25, 2026
- Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin ReactionsNCT07362914 · Phase 3 · Fudan University · starts Mar 7, 2025
- Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex CarcinomaNCT07335679 · Not reported · University Hospital, Strasbourg, France · starts Jun 10, 2025
- A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic…NCT07189403 · Phase 1 · Daiichi Sankyo · starts Nov 4, 2025
- Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose CorticosteroidsNCT07167251 · Not reported · University Hospital, Basel, Switzerland · starts Aug 25, 2025
- Cemiplimab as Maintenance Treatment for Advanced Adrenocortical CancerNCT07085572 · Phase 2 · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · starts Sep 18, 2025
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications
Approved 1
- MitotaneCytochrome P450 11A1 inhibitor
Phase 3 5
- CisplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- LinsitinibInsulin-like growth factor I receptor inhibitor
Phase 2 12 of 21
- PembrolizumabProgrammed cell death protein 1 inhibitor
- SuraminAcidic fibroblast growth factor inhibitor
- CabazitaxelTubulin inhibitor
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- PaclitaxelTubulin inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- VincristineTubulin inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- Megestrol acetateProgesterone receptor agonist
- AxitinibVascular endothelial growth factor receptor inhibitor
- LenvatinibVascular endothelial growth factor receptor inhibitor
Phase 1 or earlier 4
- CarboplatinDNA inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- RelacorilantGlucocorticoid receptor antagonist
- Edodekin alfa
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA